Stock Track | Maravai LifeSciences Plunges 5.24% Pre-market as Earnings Release Delayed, Revenue Recognition Issues

Stock Track

02-25

Maravai LifeSciences Holdings, Inc. (MRVI) stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report (Form 10-K) for the year ended December 31, 2024.

The life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9 million being recorded in the wrong quarter (Q2 2024 instead of Q3 2024).

MRVI also noted that it requires more time to complete its assessment of the effectiveness of its internal controls over financial reporting, including the remediation of a material weakness in controls over revenue recognition identified by management.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1134711971"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134711971\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1134711971?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134711971","market":"hk","top_or_hot":-1,"title":"Stock Track | Maravai LifeSciences Plunges 5.24% Pre-market as Earnings Release Delayed, Revenue Recognition Issues","media":"Stock Track","content":"<p>Maravai LifeSciences Holdings, Inc. (MRVI) stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report (Form 10-K) for the year ended December 31, 2024.</p>\n\n<p>The life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9 million being recorded in the wrong quarter (Q2 2024 instead of Q3 2024).</p>\n\n<p>MRVI also noted that it requires more time to complete its assessment of the effectiveness of its internal controls over financial reporting, including the remediation of a material weakness in controls over revenue recognition identified by management.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Maravai LifeSciences Plunges 5.24% Pre-market as Earnings Release Delayed, Revenue Recognition Issues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Maravai LifeSciences Plunges 5.24% Pre-market as Earnings Release Delayed, Revenue Recognition Issues\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-25 19:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Maravai LifeSciences Holdings, Inc. (MRVI) stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report (Form 10-K) for the year ended December 31, 2024.</p>\n\n<p>The life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9 million being recorded in the wrong quarter (Q2 2024 instead of Q3 2024).</p>\n\n<p>MRVI also noted that it requires more time to complete its assessment of the effectiveness of its internal controls over financial reporting, including the remediation of a material weakness in controls over revenue recognition identified by management.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1134711971","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134711971","pubTimestamp":1740481589,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Maravai LifeSciences Holdings, Inc.  stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report  for the year ended December 31, 2024.The life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc."},"translate_title":"由于财报发布延迟、收入确认问题，Maravai LifeSciences盘前暴跌5.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":1},"content_text":"Maravai LifeSciences Holdings, Inc. (MRVI) stock plunged 5.24% in pre-market trading on Tuesday, as the company announced the postponement of its Q4 2024 earnings release and a delay in filing its annual report (Form 10-K) for the year ended December 31, 2024.\nThe life sciences company cited several reasons for the delay, including the need for additional time to assess a potential non-cash impairment charge related to goodwill from a previous acquisition, and an error in revenue recognition that resulted in $3.9 million being recorded in the wrong quarter (Q2 2024 instead of Q3 2024).\nMRVI also noted that it requires more time to complete its assessment of the effectiveness of its internal controls over financial reporting, including the remediation of a material weakness in controls over revenue recognition identified by management.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}